

1. Maes 1999 M. Maes, Major depression and activation of the inflammatory response system, *Adv Exp Med Biol* 461 (1999), pp. 25–46.
2. Maes and Meltzer 1995 M. Maes and H.Y. Meltzer, The serotonin hypothesis of major depression. In: F.E. Bloom *et al.*, Editors, *Psychopharmacology the third generation of progress*, Raven Press, New York (1995) 993–944.
3. Schatzberg and Schildkraut 1995 A.F. Schatzberg and J.J. Schildkraut, Recent studies on norepinephrine systems on mood disorders. In: F.E. Bloom and D.J. Kupfer, Editors, *Psychopharmacology the fourth generation of progress*, Raven, New York (1995), pp. 911–922.
4. Blier 2003 P. Blier, The pharmacology of putative early-onset antidepressant strategies, *Eur Neuropsychopharmacol* 13 (2003), pp. 57–66.
5. Anguelova *et al* 2003a M. Anguelova, C. Benkelfat and G. Turecki, A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders, *Mol Psychiatry* 8 (2003), pp. 574–591.
6. Anguelova *et al* 2003b M. Anguelova, C. Benkelfat and G. Turecki, A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior, *Mol Psychiatry* 8 (2003), pp. 646–653.
7. Drevets 2001 W.C. Drevets, Neuroimaging and neuropathological studies of depression implications for the cognitive-emotional features of mood disorders, *Curr Opin Neurobiol* 11 (2001), pp. 240–249.
8. Rajkowska 2000 G. Rajkowska, Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells, *Biol Psychiatry* 48 (2000), pp. 766–777.
9. Dwivedi *et al* 2004a Y. Dwivedi, H.S. Rizavi, P.K. Shukla, J. Lyons, G. Faludi, M. Palkovits, A. Sarosi, R.R. Conley, R.C. Roberts, C.A. Tamminga and G.N. Pandey, Protein kinase A in postmortem brain of depressed suicide victims altered expression of specific regulatory and catalytic subunits, *Biol Psychiatry* 55 (2004), pp. 234–243.
10. Arango *et al* 1995 V. Arango, M.D. Underwood, A.V. Gubbi and J.J. Mann, Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims, *Brain Res* 688 (1995), pp. 121–133.
11. Escriba *et al* 2004 P.V. Escriba, A. Ozaita and J.A. Garcia-Sevilla, Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims, *Neuropsychopharmacology* 29 (2004), pp. 1512–1521.
12. Mann *et al* 2000 J.J. Mann, Y.Y. Huang, M.D. Underwood, S.A. Kassir, S. Oppenheim, T.M. Kelly, A.J. Dwork and V. Arango, A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide, *Arch Gen Psychiatry* 57 (2000), pp. 729–738.
13. Pandey *et al* 2002 G.N. Pandey, Y. Dwivedi, H.S. Rizavi, X. Ren, S.C. Pandey, C. Pesold, R.C. Roberts, R.R. Conley and C.A. Tamminga, Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims, *Am J Psychiatry* 159 (2002), pp. 419–429.
14. Zanardi *et al* 2001 R. Zanardi, F. Artigas, R. Moresco, C. Colombo, C. Messa, C. Gobbo, E. Smeraldi and F. Fazio, Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment a positron emission tomography scan study, *J Clin Psychopharmacol* 21 (2001), pp. 53–58.
15. Faludi *et al* 2000 G. Faludi, L. Du, M. Palkovits, B. Antal, P. Sotonyi and P.D. Hrdina, Serotonin transporter, serotonin-2A receptor and tryptophan hydroxylase gene polymorphisms in depressed suicide victims, *Neurobiology* 8 (2000), pp. 269–271.
16. Du *et al* 1999 L. Du, G. Faludi, M. Palkovits, E. Demeter, D. Bakish, Y.D. Lapierre, P. Sotonyi and P.D. Hrdina, Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims, *Biol Psychiatry* 46 (1999), pp. 196–201.
17. Kronfol Z, Remick D. Cytokines and the Brain: Implications for Clinical Psychiatry *Am J Psychiatry* 157:683-694, May 2000

18. Arato et al 1989 M. Arato, C.M. Banki, G. Bissette and C.B. Nemeroff, Elevated CSF CRF in suicide victims, *Biol Psychiatry* 25 (1989), pp. 355–359.
19. Arborelius et al 1999 L. Arborelius, M.J. Owens, P.M. Plotsky and C.B. Nemeroff, The role of corticotropin-releasing factor in depression and anxiety disorders, *J Endocrinol* 160 (1999), pp. 1–12.
20. Banki et al 1992 C.M. Banki, L. Karmacsi, G. Bissette and C.B. Nemeroff, CSF corticotropin-releasing hormone and somatostatin in major depression response to antidepressant treatment and relapse, *Eur Neuropsychopharmacol* 2 (1992), pp. 107–113.
21. Hauser et al 2002 P. Hauser, J. Khosla, H. Aurora, J. Laurin, M.A. Kling, J. Hill, M. Gulati, A.J. Thornton, R.L. Schultz, A.D. Valentine, C.A. Meyers and C.D. Howell, A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with Hepatitis C, *Mol Psychiatry* 7 (2002), pp. 942–947.
22. Nemeroff et al 1984 C.B. Nemeroff, E. Widerlov, G. Bissette, H. Walleus, I. Karlsson, K. Eklund, C.D. Kilts, P.T. Loosen and W. Vale, Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients, *Science* 226 (1984), pp. 1342–1344.
23. Wong et al 2000 M.L. Wong, M.A. Kling, P.J. Munson, S. Listwak, J. Licinio, P. Prolo, B. Karp, I.E. McCutcheon, T.D. Geraciotti Jr, M.D. DeBellis, K.C. Rice, D.S. Goldstein, J.D. Veldhuis, G.P. Chrousos, E.H. Oldfield, S.M. McCann and P.W. Gold, Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features relation to hypercortisolism and corticotropin-releasing hormone, *Proc Natl Acad Sci U S A* 97 (2000), pp. 325–330.
24. Nemeroff et al 1991 C.B. Nemeroff, G. Bissette, H. Akil and M. Fink, Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin, *Br J Psychiatry* 158 (1991), pp. 59–63.
25. Cook 2001 C.J. Cook, Measuring of extracellular cortisol and corticotropin-releasing hormone in the amygdala using immunosensor coupled microdialysis, *J Neurosci Methods* 110 (2001), pp. 95–101.
26. Merali et al 2004b Z. Merali, S. Khan, D.S. Michaud, S.A. Shippy and H. Anisman, Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release, *Eur J Neurosci* 20 (2004), pp. 229–239.
27. Merlo et al 1995 P.E. Merlo, M. Lorang, M. Yeganeh, D.F. Rodriguez, J. Raber, G.F. Koob and F. Weiss, Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis, *J Neurosci* 15 (1995), pp. 5439–5447.
28. Altar 1999 C.A. Altar, Neurotrophins and depression. Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression, *Trends Pharmacol Sci* 20 (1999), pp. 59–61.
29. Shirayama et al 2002 Y. Shirayama, A.C. Chen, S. Nakagawa, D.S. Russell and R.S. Duman, Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression, *J Neurosci* 22 (2002), pp. 3251–3261.
30. Dwivedi et al 2003a Y. Dwivedi, J.S. Rao, H.S. Rizavi, J. Kotowski, R.R. Conley, R.C. Roberts, C.A. Tamminga and G.N. Pandey, Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects, *Arch Gen Psychiatry* 60 (2003), pp. 273–282.
31. Uno et al 1994 H. Uno, S. Eisele, A. Sakai, S. Shelton, E. Baker, O. DeJesus and J. Holden, Neurotoxicity of glucocorticoids in the primate brain, *Horm Behav* 28 (1994), pp. 336–348.

32. Roth et al 2004 J. Roth, E.M. Harre, C. Rummel, R. Gerstberger and T. Hubschle, Signaling the brain in systemic inflammation role of sensory circumventricular organs, *Front Biosci* 9 (2004), pp. 290–300.
33. Rothwell 1999 N.J. Rothwell, Annual review prize lecture cytokines killers in the brain?, *J Physiol* 514 (1999), pp. 3–17.
34. Wang and Shuaib 2002 C.X. Wang and A. Shuaib, Involvement of inflammatory cytokines in central nervous system injury, *Prog Neurobiol* 67 (2002), pp. 161–172.
35. Dhabhar 2000 F.S. Dhabhar, Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking, *Ann N Y Acad Sci* 917 (2000), pp. 876–893.
36. Zhang et al 1998 D. Zhang, K. Kishihara, B. Wang, K. Mizobe, C. Kubo and K. Nomoto, Restraint stress-induced immunosuppression by inhibiting leukocyte migration and Th1 cytokine expression during the intraperitoneal infection of *Listeria monocytogenes*, *J Neuroimmunol* 92 (1998), pp. 139–151.
37. Nagatsu et al 2000 T. Nagatsu, M. Mogi, H. Ichinose and A. Togari, Changes in cytokines and neurotrophins in Parkinson's disease, *J Neural Transm Suppl* 60 (2000), pp. 277–290.
38. McDonald et al 2003 W.M. McDonald, I.H. Richard and M.R. DeLong, Prevalence, etiology, and treatment of depression in Parkinson's disease, *Biol Psychiatry* 54 (2003), pp. 363–375.
39. Mullar and Ackenheil 1998 N. Mullar and M. Ackenheil, Psychoneuroimmunology and the cytokine action in the CNS implications for psychiatric disorders, *Prog Neuropsychopharmacol Biol Psychiatry* 22 (1998), pp. 1–33.
40. Nassberger and Traskman-Bendz 1993 L. Nassberger and L. Traskman-Bendz, Increased soluble interleukin-2 receptor concentrations in suicide attempters, *Acta Psychiatr Scand* 88 (1993), pp. 48–52.
41. Sluzewska 1999 A. Sluzewska, Indicators of immune activation in depressed patients, *Adv Exp Med Biol* 461 (1999), pp. 59–74.
42. Yirmiya et al 1999 R. Yirmiya, J. Weidenfeld, Y. Pollak, M. Morag, A. Morag, R. Avitsur, O. Barak, A. Reichenberg, E. Cohen, Y. Shavit and H. Ovadia, Cytokines, "depression due to a general medical condition," and antidepressant drugs, *Adv Exp Med Biol* 461 (1999), pp. 283–316.
43. Valentine et al 1995 A.D. Valentine, C.A. Meyers and M. Talpaz, Treatment of neurotoxic side effects of interferon-alpha with naltrexone, *Cancer Invest* 13 (1995), pp. 561–566.
44. Dieperink et al 2003 E. Dieperink, S.B. Ho, P. Thuras and M.L. Willenbring, A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C, *Psychosomatics* 44 (2003), pp. 104–112.
45. Dieperink et al 2000 E. Dieperink, M. Willenbring and S.B. Ho, Neuropsychiatric symptoms associated with hepatitis C and interferon alpha A review, *Am J Psychiatry* 157 (2000), pp. 867–876.
46. Denicoff et al 1987 K.D. Denicoff, D.R. Rubinow, M.Z. Papa, L. Simpson, L.A. Seipp, M.T. Lotze, A.E. Chang, D. Rosenstein and S.A. Rosenberg, The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells, *Ann Intern Med* 107 (1987), pp. 293–300.
47. Meyers and Valentine 1995 C.A. Meyers and A.D. Valentine, Neurological and psychiatric adverse effects of immunological therapy, *CNS Drugs* 3 (1995), pp. 56–68.
48. Miyaoka et al 1999 H. Miyaoka, T. Otsubo, K. Kamijima, M. Ishii, M. Onuki and K. Mitamura, Depression from interferon therapy in patients with hepatitis C, *Am J Psychiatry* 156 (1999), p. 1120.
49. Musselman et al 2001 D.L. Musselman, D.H. Lawson, J.F. Gurnick, A.K. Manatunga, S. Penna, R.S. Goodkin, K. Greiner, C.B. Nemeroff and A.H. Miller, Paroxetine for the prevention of depression induced by high-dose interferon alfa, *N Engl J Med* 344 (2001), pp. 961–966.

50. Capuron et al 2002 L. Capuron, J.F. Gurnick, D.L. Musselman, D.H. Lawson, A. Reemsnyder, C.B. Nemeroff and A.H. Miller, Neurobehavioral effects of interferon-alpha in cancer patients phenomenology and paroxetine responsiveness of symptom dimensions, *Neuropsychopharmacology* 26 (2002), pp. 643–652.
51. Capuron et al 2000 L. Capuron, A. Ravaud and R. Dantzer, Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy, *J Clin Oncol* 18 (2000), pp. 2143–2151.
52. Wichers and Maes 2002 M. Wichers and M. Maes, The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans, *Int J Neuropsychopharmacol* 5 (2002), pp. 375–388.
53. Maes and Bonaccorso 2004 M. Maes and S. Bonaccorso, Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C, *Acta Psychiatr Scand* 109 (2004), pp. 126–131.
54. Schramm et al 2000 T.M. Schramm, B.R. Lawford, G.A. Macdonald and W.G. Cooksley, Sertraline treatment of interferon-alfa-induced depressive disorder, *Med J Aust* 173 (2000), pp. 359–361.
55. Kraus et al 2002 M.R. Kraus, A. Schafer, H. Faller, H. Csef and M. Scheurlen, Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C, *Aliment Pharmacol Ther* 16 (2002), pp. 1091–1099.
56. Maes et al 2001 M. Maes, L. Capuron, A. Ravaud, N. Gualde, E. Bosmans and B. Egyed et al., Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy, *Neuropsychopharmacology* 24 (2001), pp. 130–140.
57. Capuron et al 2003 L. Capuron, C.L. Raison, D.L. Musselman, D.H. Lawson, C.B. Nemeroff and A.H. Miller, Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy, *Am J Psychiatry* 160 (2003), pp. 1342–1345.
58. Bonaccorso et al 2002a S. Bonaccorso, V. Marino, M. Biondi, F. Grimaldi, F. Ippolit and M. Maes, Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus, *J Affect Disord* 72 (2002), pp. 237–241. Bonaccorso et al 2002b S.
59. Bonaccorso, V. Marino, A. Puzella, M. Pasquini, M. Biondi, M. Artini, C. Almerighi, R. Verkerk, H. Meltzer and M. Maes, Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system, *J Clin Psychopharmacol* 22 (2002), pp. 86–90.
60. Menkes and MacDonald 2000 D.B. Menkes and J.A. MacDonald, Interferons, serotonin and neurotoxicity, *Psychol Med* 30 (2000), pp. 259–268.
61. Wichers and Maes 2004 M.C. Wichers and M. Maes, The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression, *J Psychiatry Neurosci* 29 (2004), pp. 11–17.
62. Allan and Rothwell 2001 S.M. Allan and N.J. Rothwell, Cytokines and acute neurodegeneration, *Nat Rev Neurosci* 2 (2001), pp. 734–744.
63. Varfolomeev and Ashkenazi 2004 E.E. Varfolomeev and A. Ashkenazi, Tumor necrosis factor an apoptosis JuNKie?, *Cell* 116 (2004), pp. 491–497.
64. Silverstein et al 1997 F.S. Silverstein, J.D. Barks, P. Hagan, X.H. Liu, J. Ivacko and J. Szaflarski, Cytokines and perinatal brain injury, *Neurochem Int* 30 (1997), pp. 375–383.
65. Allan 2002 S.M. Allan, Varied actions of proinflammatory cytokines on excitotoxic cell death in the rat central nervous system, *J Neurosci Res* 67 (2002), pp. 428–434.
66. Pawate et al 2004 S. Pawate, Q. Shen, F. Fan and N.R. Bhat, Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma, *J Neurosci Res* 77 (2004), pp. 540–551.

67. Wichers and Maes 2004 M.C. Wichers and M. Maes, The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression, *J Psychiatry Neurosci* 29 (2004), pp. 11–17.
68. Hanisch 2002 U.K. Hanisch, Microglia as a source and target of cytokines, *Glia* 40 (2002), pp. 140–155.
69. Pocock and Liddle 2001 J.M. Pocock and A.C. Liddle, Microglial signalling cascades in neurodegenerative disease, *Prog Brain Res* 132 (2001), pp. 555–565.
70. Vezzani et al 2002 A. Vezzani, D. Moneta, C. Richichi, M. Aliprandi, S.J. Burrows, T. Ravizza, C. Perego and M.G. De Simoni, Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis, *Epilepsia* 43 (2002), pp. 30–35.
71. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. *Science*. 1999 Dec 17;286(5448):2352-5.
72. Kaul, M., Garden, G., Lipton, S., 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature* 410, 988–994.
73. Peruzzi, F., Bergonzini, V., Aprea, S., Reiss, K., Sawaya, B.E., Rappaport, J., Amini, S., Khalili, K., 2005. Cross talk between growth factors and viral and cellular factors alters neuronal signaling pathways: implication for HIV-associated dementia. *Brain Res. Brain Res. Rev.* 50, 114–125.
74. Shapshak, P., Duncan, R., Minagar, A., Rodriguez de la Vega, P., Stewart, R.V., Goodwin, K., 2004. Elevated expression of IFN-gamma in the HIV-1 infected brain. *Front. Biosci.* 9, 1073–1081.
75. Benveniste, E.N., 1994. Cytokine circuits in brain. In: Price, R.W., Perry, S.W. (Eds.), *HIV, AIDS and the Brain*. Raven Press, Ltd., New York City, pp. 71–88.
76. Kim, T.K., Maniatis, T., 1996. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. *Science* 273, 1717–1719.
77. Lee, K.Y., Anderson, E., Madani, K., Rosen, G.D., 1999. Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. *FEBS Lett.* 459, 323–326.
78. Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, Ehrhart J, Shytle D, Fernandez F, Tan J. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of JAK/STAT1 signaling and implications for HIV-associated dementia. *Brain Res.* 2006 Dec 6;1123(1):216-25. Epub 2006 Oct 31.
79. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J, Fernandez F. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. *Brain Res Bull.* 2004 Aug 30;64(2):165-70
80. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, Leonard BE. Th1, Th2 and Th3 cytokine alteration in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2004 Nov;28(7):1129-34.
81. Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. *Croat Med J.* 2005 Apr;46(2):268-74.
82. Miyahara S, Komori T, Fujiwara R, Shizuya K, Yamamoto M, Ohmori M, Okazaki Y (2000) Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. *Life Sci* 66: PL93–PL98.
83. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, Maier SF (1998) Exposure to acute stress induces brain interleukin-1 β protein in the rat. *J Neurosci* 19:2799–2805.
84. Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, Aiso S, Kato R, Asai M (1995) Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotrophic hormone and in release of hypothalamic monoamines in the rat. *J Neurosci* 15:1961–1970

85. Barrientos RM, Sprunger DB, Campeau S, Watkins LR, Rudy JW, Maier SF (2004) BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration. *J Neuroimmunol* 155:119–126.
86. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM (2000) Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. *Eur J Neurosci* 12:1891–1899.
87. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R (2002) Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. *Brain-derived neurotrophic factor. Brain* 125:2381–2391.
88. Obara Y, Nakanata N (2002) The signaling pathway of neurotrophic factor biosynthesis. *Drug News Perspect* 15:290–298. Shaw KN, Commins S, O'Mara SM (2001) Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. *Behav Brain Res* 124:47–54.
89. Shaw KN, Commins S, O'Mara SM (2001) Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. *Behav Brain Res* 124:47–54.